• How promising is Remdesivir?

  • Nov 19 2020
  • Durée: 15 min
  • Podcast

How promising is Remdesivir?

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • Over a year since the first recorded case of Covid-19 in humans, only one antiviral drug is approved for its treatment. The Telegraph’s Global Health Security team speak to Dr Michael Elliot, Vice President of Medical Affairs at Gilead Sciences, the company that manufactures Remdesivir. They discuss how useful it is, whether big pharma is solely driven by profit and the prognosis for severe coronavirus sufferers in the second wave.

    Read more on the Oxford vaccine: https://bit.ly/2UVfPet |

    Read more on Brexit talks: https://bit.ly/36V8f8Y |

    Read more on the new quarantine-free list: https://bit.ly/3lMs88H |

    For 30 days' free access to The Telegraph: https://www.telegraph.co.uk/audio |

    Email: coronaviruspodcast@telegraph.co.uk |

    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.


    Hosted on Acast. See acast.com/privacy for more information.
    Voir plus Voir moins
Voir plus Voir moins
activate_Holiday_promo_in_buybox_DT_T2

Ce que les auditeurs disent de How promising is Remdesivir?

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.